Carcinogenicity of cardiovascular drugs

Current Hypertension Reports

Volumn 1, Issue 3, 1999, Pages 212-218

  Grossman, Ehud ^a   Messerli, Franz H ^b   Goldbourt, Uri ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RESERPINE;

BREAST TUMOR; CHEMICALLY INDUCED DISORDER; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; NEOPLASM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BREAST NEOPLASMS; CALCIUM CHANNEL BLOCKERS; CARCINOMA, RENAL CELL; DIURETICS; HUMANS; KIDNEY NEOPLASMS; NEOPLASMS; RESERPINE;

EID: 0033139642     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0023-8     Document Type: Review

References (73)

1. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults:principal results. BMJ 1992, 304: 405-411.
2. Staessen J, Bulpitt C, Clement D, et al.: Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ 1989, 298: 1552-1556.
3. SHEP Cooperative Ressearch Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265: 3255-3264.
4. Williams RR, Feinleib M, Connor RJ, Stegens NL: Case-controlled study of antihypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program. J Natl Cancer Inst 1978, 61: 327-335.
5. Fraser GE, Phillips RL, Beeson WL: Hypertension, antihypertensive medication, and risk of renal carcinoma in California Seventh-Day Adventists. Int J Epidemiol 1990, 19: 832-838.
6. Grove JS, Nomura A, Severson RK, Stemmermann GN: The association of blood pressure with cancer incidence in a prospective study. Am J Epidemiol 1991, 134: 942-947.
7. McCredie M, Stewart JH: Risk factors for kidney cancer in New South Wales, Australia.II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 1992, 3: 323-331.
8. Suadicani P, Hein HO, Gyntelberg F: Is the use of antihypertensives and sedatives a major risk factor for colorectal cancer? Scand J Gastroenterol 1993, 28: 475-481.
9. McLaughlin JK, Chow WH, Mandel JS, et al.: International renal-cell cancer study. VIII. Role of diuretics, other antihypertensive medications, and hypertension. Int J Cancer 1995, 63: 216-221.
10. Chow WH, McLaughlin JK, Mandel JS, et al.: Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol Biomarkers Prev 1995, 4: 327-331.
11. Peeters PH, van Noord PA, Hoes AW, Grobbee DE: Hypertension, antihypertensive drugs, and mortality from cancer among women. J Hypertens 1998, 16: 941-947.
12. Rosenberg L, Rao RS, Palmer JR, et al.: Calcium channel blockers and the risk of cancer. JAMA 1998, 279: 1000-1004.
13. Boston Collaborative Drug Surveillance Program: Reserpine and breast cancer. Lancet 1974, 2: 669-671.
14. Mellemgaard A, Moller H, Olsen JH: Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control 1992, 3: 309-312.
15. Kreiger N, Marrett LD, Dodds L, et al.: Risk factors for renal cell carcinoma: results of a population-based case-controlled study. Cancer Causes Control 1993, 4: 101-410.
16. Mellemgaard A, Niwa S, Mehl ES, et al.: Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 1994, 23: 923-930.
17. Finkle WD, McLaughlin JK, Rasgon SA, et al.: Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control 1993, 4: 555-558.
18. Hiatt RA, Tolan K, Quesenberry CP Jr: Renal cell carcinoma and thiazide use: a historical, case-controlled study (California, USA). Cancer Causes Control 1994, 5: 319-325.
19. Weinmann S, Glass AG, Weiss NS, et al.: Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994, 140: 792-804.
20. Pahor M, Guralnik JM, Salive ME, et al.: Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1966, 9: 695-699.
21. Pahor M, Guralnik JM, Ferrucci L, et al.: Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996, 348: 493-497.
22. Fitzpatrick AL, Daling JR, Furberg CD, et al.: Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997, 80: 1438-1447.
23. Dyer AR, Stamler J, Berkson DM, et al.: High blood pressure: a risk factor for cancer mortality? Lancet 1975, 1: 1051-1056.
24. Labarthe DR, O'Fallon WM: Reserpine and breast cancer: a community-based longitudinal study of 2000 hypertensive women. JAMA 1980, 243: 2304-2310.
25. Curb JD, Hardy RJ, Labarthe DR, et al.: Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. Hypertension 1982, 4: 307-311.
26. Friedman GD: Rauwolfia and breast cancer: no relation found in long term users age fifty and over. J Chronic Dis 1983, 36: 367-370.
27. Shapiro S, Parsells JL, Rosenberg L, et al.: Risk of breast cancer in relation to the use of rauwolfia alkaloids. Eur J Clin Pharmacol 1984, 26: 143-146.
28. Cazenave JP, Reimers HJ, Perey DY, Mustard JF: Rauwolfia derivatives and breast cancer. Lancet 1974, 2: 1571-1572.
29. Tsutsui T, Taguchi S, Hasegawa K, et al.: Reserpine-induced cell transformation without detectable genetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 1994, 15: 11-14.
30. Byar DP, Blackard CE: Reserpine and prostatic cancer. Urology 1975, 5: 158-159.
31. Bucher JR: NTP technical report on the toxicology and carcinogenesis studies of furosemide in F344/N rats and B6C3F mice. Research Triangle Park, NC: National Toxicology Program; 1989. US Dept of Health and Human Services publication NTP TR 356.
32. Yu MC, Mack RM, Hanisch R, et al.: Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986, 77: 351-356.
33. Prineas RJ, Folsom AR, Zhang ZM, et al.: Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology 1997, 8: 31-36.
34. Heath CW Jr, Lally CA, Calle EE, et al.: Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol 1997, 145: 607-613.
35. Zavanella T, Radaelli,G, Girotti P, et al.: Evaluation of the tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. Carcinogenesis 1994, 15: 2531-2539.
36. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317: 713-720.
37. Hole DJ, Hawthorne VM, Isles CG, et al.: Incidence of and mortality from cancer in hypertensive patients. BMJ 1993, 306: 609-611.
38. Fletcher AE, Beevers DG, Bulpitt CJ, et al.: Cancer mortality and atenolol treatment. BMJ 1993, 306: 622-623.
39. Jick H, Jick S, Derby LE, et al.: Calcium-channel blockers and risk of cancer. Lancet 1997, 349: 525-528.
40. Messerli FH, Grossman E: Antihypertensive agents and the risk of cancer [letter]. JAMA 1998, 280:600.
41. Muldoon MF, Kuller LH: Hypertension and cancer. BMJ 1993, 306: 598-599.
42. Reddy MK, Baskaran K, Molteni A: Inhibitors of angiotensinconverting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995, 210: 221-226.
43. Small W, Ward WF, Kim YT, et al.: Captopril inhibits proliferation of human mammary ductal carcinoma cells in culture. FASEB J 1994, 8:A672.
44. Chen L, Re RN, Prakash O, Mondal D: Angiotensin converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991, 196: 280-3.
45. Ward WF, Molteni A, Ts'ao CH, Hinz CM: The effect of captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol 1990, 63: 349-354.
46. Ward WF, Molteni A, Kim YT, et al.: Captopril inhibits mitosis and growth of diethylnitrosamine-induced preneoplastic hepatic foci in F344 rats. FASEB J 1992, 6:A1932.
47. Bastiaens MT, Zwan NV, Verschueren GL, et al.: Three cases of pemphigus vegetans: induction by enalapril-association with internal malignancy. Int J Dermatol 1994, 33: 168-171.
48. Larbre JP, Nicolas JF, Collet P, et al.: Kaposi's sarcoma in a patient with rheumatoid arthritis possible responsibility of captopril in the development of lesions. J Rheumatol 1991, 18: 476-7.
49. Puppin D Jr, Rybojad M, de la Chapelle C, Morel P: Kaposi's sarcoma associated with captopril. Lancet 1990, 336: 1251-1252.
50. Carroll J, Thaler M, Grossman E, et al.: Generalized postular eruption associated with converting enzyme inhibitor therapy. Cutis 1995, 56: 276-278.
51. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992, 327: 685-691.
52. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensinconverting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting- Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334: 939-945.
53. Lever AF, Hole DJ, Gillis CR, et al.: Do inhibitors of angiotensin- I-converting enzyme protect against risk of cancer? Lancet 1998, 352: 179-184.
54. Mickisch GH, Kossig J, Keilhauer G, et al.: Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 1990, 50: 3670-3674.
55. Al-Shabanah OA, Osman AM, Al Harbi MM, et al.: Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites carcinoma cells. Chemotherapy 1995, 41: 368-377.
56. Al-Gharably NM, Osman AM, Al-Shabanah OA, et al.: Potentiation of doxorubicin cytotoxicity by the calcium channel blocker verapamil in Ehrlich ascites cells. Chemotherapy 1993, 39: 410-415.
57. Taylor JM, Simpson RU: Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992, 52: 2413-2418.
58. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al.: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990, 335: 1109-1113.
59. Jonas M, Goldbourt U, Boyko V, et al.: Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther 1998, 12: 177-181.
60. Hole DJ, Gillis CR, McCallum IR, et al.: Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens 1998, 16: 119-124.
61. Brandenburg NA, Backstorm JT, Hinkle RL: Calcium channel blockers and cancer: the evidence against an association. Am J Hypertens 1996, 9: 1049-1050.
62. Messerli FH, Grossman E: Do calcium antagonists increase the risk for malignancies? J Am Coll Cardiol 1998, 31: 809-810.
63. Borhani NO, Mercuri M, Borhani PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996, 276: 785-791.
64. Packer M, O'Connor CM, Ghali JK, et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996, 335: 1107-1114.
65. Gong L, Zhang W, Zhu Y, et al.: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996, 14: 1237-1245.
66. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350: 757-764.
67. Braun S, Boyko V, Behar S, et al.: Calcium channel blocking agents and risk of cancer in patients with coronary heart disease: Benzafibrate Infarction Prevention (BIP) Study Research Group. J Am Coll Cardiol 1998, 31: 804-808.
68. Olsen JH, Toft Sorensen HT, Friis S, et al.: Cancer risk in users of calcium channel blockers. Hypertension 1997, 29: 1091-1094.
69. Bhat UG, Winter MA, Pearce HL, Beck WT: Lymphoma and methyldopa therapy. J Am Geriatr Soc 1995, 43: 941-942.
70. Kaufman DW, Kelly JP, Rosenberg L, et al.: Hydralazine and breast cancer. J Natl Cancer Inst 1987, 78: 243-246.
71. Kaufman DW, Kelly JP, Rosenberg L, et al.: Hydralazine use in relation to cancers of the lung, colon, and rectum. Eur J Clin Pharmacol 1989, 36: 259-264.
72. Chaplin DJ: Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy. J Natl Cancer Inst 1989, 81: 618-622.
73. Lee YS, Wurster RD: Mechanism of potentiation of LY83583- induced growth inhibition by sodium nitroprusside in human brain tumor cells. Cancer Chemother Pharmacol 1995, 36: 341-344.